All In Biotech

Investigational drug · Phase 2

TQB2916

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Soft Tissue Sarcoma, Melanoma, Pancreatic Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: May 8, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

3

Any phase or sponsor naming "TQB2916"

First trial start

2024

Jul 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "TQB2916", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Soft Tissue Sarcoma
  • Melanoma
  • Pancreatic Cancer

Approved drugs for the same conditions: Melanoma · Pancreatic cancer · Sarcoma · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "TQB2916" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Soft Tissue Sarcoma

  • L19TNFL19IL2, OnfekafuspPhase 310 trials

    Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III

  • ChiauranibCS2164Phase 33 trials

    Chipscreen Biosciences, Ltd. · Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma

  • 1.0% IP-001IP-001Phase 32 trials

    Immunophotonics, Inc. · Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer

  • Tigilanol TiglateEBC-46Phase 22 trials

    QBiotics Group Limited · Soft Tissue Sarcoma, Head and Neck Cancer

  • CYT-0851Phase 21 trial

    Cyteir Therapeutics, Inc. · Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.